Reshma Kewalramani, Vertex CEO (BIO via YouTube)
Vertex strikes out on its latest big shot at a rare genetic disease. But they're going to keep on swinging
It’s been several months since Vertex culled one of its small molecules for alpha-1 antitrypsin deficiency (AATD), taking a big hit after evidence of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.